P

Poolbeg Pharma PLC
LSE:POLB

Watchlist Manager
Poolbeg Pharma PLC
LSE:POLB
Watchlist
Price: 7.15 GBX Market Closed
Market Cap: 35.8m GBX
Have any thoughts about
Poolbeg Pharma PLC?
Write Note

Poolbeg Pharma PLC
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Poolbeg Pharma PLC
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
P
Poolbeg Pharma PLC
LSE:POLB
Research & Development
-ÂŁ1.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Research & Development
-ÂŁ6B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-6%
AstraZeneca PLC
LSE:AZN
Research & Development
-$11B
CAGR 3-Years
-31%
CAGR 5-Years
-14%
CAGR 10-Years
-9%
Verona Pharma PLC
NASDAQ:VRNA
Research & Development
-$40.8m
CAGR 3-Years
15%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Research & Development
-$146m
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
-14%
Dechra Pharmaceuticals PLC
LSE:DPH
Research & Development
-ÂŁ57.5m
CAGR 3-Years
-27%
CAGR 5-Years
-26%
CAGR 10-Years
-22%
No Stocks Found

Poolbeg Pharma PLC
Glance View

Market Cap
35.8m GBX
Industry
Pharmaceuticals

Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is focused on targeting the medical needs to treat and prevent infectious disease. The firm's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The firm's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The firm is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.

POLB Intrinsic Value
2.43 GBX
Overvaluation 66%
Intrinsic Value
Price
P

See Also

What is Poolbeg Pharma PLC's Research & Development?
Research & Development
-1.7m GBP

Based on the financial report for Dec 31, 2023, Poolbeg Pharma PLC's Research & Development amounts to -1.7m GBP.

What is Poolbeg Pharma PLC's Research & Development growth rate?
Research & Development CAGR 1Y
24%

Over the last year, the Research & Development growth was 24%.

Back to Top